HOME >> BIOLOGY >> NEWS
Wellcome Trust and GlaxoSmithKline announce partnership to target drug-resistant hospital infections

The Wellcome Trust and GlaxoSmithKline (GSK) today announced a collaboration to develop a new class of antibacterials to combat the rise of certain drug-resistant hospital-acquired infections, including those that lead to pneumonia. The collaboration is part of the Wellcome Trusts Seeding Drug Discovery initiative, aimed at tackling unmet medical needs.

GSK has received a 4 million award from the Trust to accelerate development of compounds for the treatment of Gram-negative bacteria which are becoming increasingly resistant to multiple antibacterials. GSK will make a matching contribution in staff, equipment, and other programme costs. The Trust will receive a financial consideration on any commercial product resulting from the collaboration.

"Our ability to tackle drug-resistant infections is reaching crisis level with few new antimicrobial agents on the horizon," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "Antibacterials are expensive to develop and may be held in reserve, limiting their market potential. It can be difficult, therefore, for companies to recoup their outlay in R&D costs.

This is where the Wellcome Trust believes it can make a difference through partnership. GSK has demonstrated a continuing commitment to discover and develop new antibacterials, aimed at addressing the growing threat of resistance. Our partnership will further support its research programmes."

The research will target Gram-negative bacteria, such as Pseudomonas, Klebsiella and Acinetobacter, which are increasingly resistant to available antibacterials and commonly cause hospital-acquired pneumonia and septic shock, particularly in patients in intensive care units. Without adequate therapy, patients often confront a poor prognosis mortality is high, and recovery, when it occurs, can be long and complicated.

Dr Patrick Vallance, Senior Vice President of Drug Discovery at GSK, commented: Infectio
'"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
29-Apr-2007


Page: 1 2

Related biology news :

1. Burroughs Wellcome Fund awards $14M to support physician-scientists
2. Burroughs Wellcome fund awards $8.25 million in grants to physician-scientists
3. Major Wellcome Trust award to take science from the bench to the bedside
4. A Wellcome brain gain for world leading neuroscience lab
5. Burroughs Wellcome Fund to support Project Suc-SEED at CIIT Centers for Health Research
6. BioMed Central applauds Wellcomes leadership on Open Access
7. Yale scientist studying virus infections named Burroughs Wellcome Investigator
8. Wilson Center and Pew Charitable Trusts expand efforts to examine risks/benefits of nanotechnology
9. Trusting your instincts leads you to the right answer
10. Leeds Teaching Hospitals NHS Trust to host press conference call/webcast on data published in NEJM
11. GlaxoSmithKlines rotavirus vaccine candidate shown effective

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2020)... ... January 24, 2020 , ... The Rockies ... capital resources to support early-stage bioscience companies in the state. , ... to find the funding they need to innovate and grow. This program ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... red blood cells from stem cells. The red blood cells are made ... strictly controlled conditions, for transfusion therapy and replaces the need for a human ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, ... a consortium of over 100 partner organizations from industry, government, academia and ...
Breaking Biology News(10 mins):
(Date:12/31/2019)... ... December 31, 2019 , ... Vici Health ... development lab in Maryland. Emphasis will be in expanding capabilities in both ... Health Sciences will be well positioned to meet the growing demand for its ...
(Date:12/27/2019)... ... December 27, 2019 , ... Vici Health Sciences is announcing ... that offers patients and healthcare providers options in the treatment of chronic ... with doctors and managed care professionals and developed at Vici’s R&D facility ...
(Date:12/18/2019)... ... , ... Tune in to CNBC on Saturday, December 28th at 11:00aET to ... more information on this program. , With a look at Avatar Partners , ... to increase the efficiency, safety and effectiveness of equipment, systems, and processes for the ...
(Date:12/4/2019)... ... December 03, 2019 , ... ... and services, today announced a partnership with the Recombinant Antibody Network (RAN), a ... and UC San Francisco (UCSF) with a common goal to generate recombinant antibodies ...
Breaking Biology Technology:
Cached News: